| Literature DB >> 2579440 |
G Bonadonna, S Viviani, P Valagussa, V Bonfante, A Santoro.
Abstract
CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible.Entities:
Mesh：
Substances：
Year: 1985 PMID： 2579440
Source DB: PubMed Journal: Semin Oncol ISSN： 0093-7754 Impact factor: 4.929